Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · see citing works

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455 · see citing works

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · see citing works

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377 · see citing works

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368 · see citing works

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Sarker, D., Ang, J. E., Baird, R. D., Kristeleit, R. S., Shah, K. J., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G. G., Ware, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 361 · see citing works

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324 · see citing works

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 323 · see citing works

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 310 · see citing works

The Akt kinase: Molecular determinants of oncogenicity

Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P. N., & Vogt, P. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14950 · Cited by 297 · see citing works

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Raynaud, F. I., Eccles, S. A., Patel, S. K., Alix, S., Box, G., Chuckowree, I., Folkes, A. J., Gowan, S. M., Brandon, A. D. H., Stefano, F. D., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 273 · see citing works

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Sos, M. L., Fischer, S., Ullrich, R. T., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J. M., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 255 · see citing works

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242 · see citing works

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Spoerke, J. M., O'Brien, C. L., Huw, L. Y., Koeppen, H., Fridlyand, J., Brachmann, R. K., Haverty, P. M., Pandita, A., Mohan, S., Sampath, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2347 · Cited by 181 · see citing works

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

McCubrey, J. A., Steelman, L. S., Kempf, C., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 173 · see citing works

Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies

Saldanha, G. S., Potter, L., DaForno, P., & Pringle, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2447 · Cited by 130 · see citing works

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 116 · see citing works

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

Tolcher, A. W., Peng, W., & Calvo, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0349 · Cited by 99 · see citing works

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0530-5 · Cited by 98 · see citing works

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Rosen, L. S., LoRusso, P. M., Ma, W. W., Goldman, J. W., Weise, A. M., Colevas, A. D., Adjei, A. A., Yazji, S., Shen, A., Johnston, S. H., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0374-3 · Cited by 88 · see citing works

Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

Salphati, L., Wong, H., Belvin, M. P., Bradford, D., Edgar, K. A., Prior, W. W., Sampath, D., & Wallin, J. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032912 · Cited by 84 · see citing works

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. A., Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0377-0 · Cited by 81 · see citing works

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Wong, H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J., Yu, P., Li, C., Rosario, G. D., Choo, E. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0445 · Cited by 80 · see citing works

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma

Mohan, S., Broek, R. V., Shah, S., Eytan, D. F., Pierce, M., Carlson, S. G., Coupar, J. F., Zhang, J., Cheng, H. W., Chen, Z., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3377 · Cited by 70 · see citing works

A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.

Juric, D., Soria, J., Sharma, S., Banerji, U., Azaro, A., Desai, J., Ringeisen, F. P., Kaag, A., Radhakrishnan, R., Hourcade‐Potelleret, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9051 · Cited by 55 · see citing works

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

Choo, E. F., Ng, C. M., Berry, L., Belvin, M. P., Lewin‐Koh, N., Merchant, M. A., & Salphati, L. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1988-6 · Cited by 30 · see citing works

A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.

Ramanathan, R. K., Hoff, D. D. V., Eskens, F. A. L. M., Blumenschein, G. R., Richards, D., Renshaw, F. G., Rajagopalan, P., Kelly, A. T., Peña, C. E., & Mross, K. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2588 · Cited by 16 · see citing works

Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage

Jokinen, E., & Koivunen, J. P. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3071 · Cited by 15 · see citing works

Determination of cobimetinib in human plasma using protein precipitation extraction and high-performance liquid chromatography coupled to mass spectrometry

Deng, Y., Musib, L. C., Choo, E. F., Chapple, M., Burke, S., Johnson, J. E., Eppler, S., & Dean, B. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.09.034 · Cited by 9 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 785 · see citing works

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments

Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 332 · see citing works

MEK inhibitors for the treatment of non-small cell lung cancer

Han, J., Liu, Y., Yang, S., Wu, X., Li, H., & Wang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01025-7 · Cited by 291 · see citing works

Emerging strategies to target RAS signaling in human cancer therapy

Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 231 · see citing works

Molecular hybridization: a powerful tool for multitarget drug discovery

Pinheiro, P. D. S. M., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 224 · see citing works

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment

Leiphrakpam, P., & Are, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063178 · Cited by 193 · see citing works

Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy

Soltan, O. M., Shoman, M. E., Abdel‐Aziz, S. A., Narumi, A., Konno, H., & Abdel‐Aziz, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113768 · Cited by 148 · see citing works

Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects

Stanciu, S., Radu, F. I., Ștefani, C., Miricescu, D., Stănescu-Spînu, I.-I., Greabu, M., Totan, A., & Jinga, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710132 · Cited by 144 · see citing works

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121 · see citing works

Strategies to tackle RAS-mutated metastatic colorectal cancer

Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86 · see citing works

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · see citing works

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

Leroux, C., & Konstantinidou, G. (2021) · Cancers · doi:10.3390/cancers13040799 · Cited by 76 · see citing works

Disrupting cellular memory to overcome drug resistance

Harmange, G., Hueros, R. A. R., Schaff, D. L., Emert, B. L., Saint-Antoine, M., Kim, L. C., Niu, Z., Nellore, S., Fane, M. E., Alicea, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41811-8 · Cited by 56 · see citing works

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer

Middleton, G., Robbins, H. L., André, F., & Swanton, C. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.004 · Cited by 58 · see citing works

A landscape of response to drug combinations in non-small cell lung cancer

Nair, N. U., Greninger, P., Zhang, X., Friedman, A. A., Amzallag, A., Cortez, E., Sahu, A. D., Lee, J. S., Dastur, A., Egan, R. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39528-9 · Cited by 58 · see citing works

Phosphoinositide 3-kinase (PI3K) classes: From cell signaling to endocytic recycling and autophagy

Safaroghli‐Azar, A., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175827 · Cited by 58 · see citing works

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Ramanathan, R. K., Hoff, D. D. V., Eskens, F. A. L. M., Blumenschein, G. R., Richards, D., Genvresse, I., Reschke, S., Granvil, C. P., Skubala, A., Peña, C. E., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00714-0 · Cited by 54 · see citing works

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

Avery, T. Y., Köhler, N., Zeiser, R., Brummer, T., & Ruess, D. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931774 · Cited by 51 · see citing works

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance

Vitale, S. R., Martorana, F., Stella, S., Motta, G., Inzerilli, N., Massimino, M., Tirrò, E., Manzella, L., & Vigneri, P. G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103334 · Cited by 48 · see citing works

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

Huang, X., You, L., Nepovimová, E., Psotka, M., Maliňák, D., Valko, M., Sivák, L., Korábečný, J., Heger, Z., Adam, V., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2237209 · Cited by 42 · see citing works

Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy

Han, B., Lin, X., & Hu, H. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-29 · Cited by 44 · see citing works

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma

Delyon, J., Lebbé, C., & Dumaz, N. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000606 · Cited by 42 · see citing works

Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer

Kumar, S., Principe, D. R., Singh, S. K., Viswakarma, N., Sondarva, G. V., Rana, B., & Rana, A. (2020) · Pharmaceuticals · doi:10.3390/ph13010009 · Cited by 38 · see citing works

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 35 · see citing works

ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer

Köhler, J., Zhao, Y., Li, J., Gokhale, P. C., Tiv, H. L., Knott, A., Wilkens, M. K., Soroko, K. M., Lin, M., Ambrogio, C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0531 · Cited by 36 · see citing works

Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer

Wylaź, M., Kaczmarska, A., Pajor, D., Hryniewicki, M., Gil, D., & Dulińska-Litewka, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115676 · Cited by 33 · see citing works

Functional and structural insights into RAS effector proteins

Mozzarelli, A. M., Simanshu, D. K., & Castel, P. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.06.027 · Cited by 31 · see citing works

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 30 · see citing works

Targeting NUPR1-dependent stress granules formation to induce synthetic lethality in KrasG12D-driven tumors

Santofimia‐Castaño, P., Fraunhoffer, N. A., Liu, X., Bessone, I. F., di Magliano, M. P., Audebert, S., Camoin, L., Estarás, M., Brenière, M., Modesti, M., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00032-2 · Cited by 27 · see citing works

Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects

Rodrigues, D. A., Pinheiro, P. D. S. M., & Fraga, C. A. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000643 · Cited by 27 · see citing works

Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy

Yu, C., Zhang, M., Song, J., Zheng, X., Xu, G., Bao, Y., Lan, J., Luo, D., Hu, J., Li, J. J., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00013-0 · Cited by 26 · see citing works

Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology

Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 28 · see citing works

XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer

Xu, S., Sun, X., Luo, L., Yang, Y., Guo, Q., Tang, S., Jiang, Z., Li, Y., Han, J., Gan, W., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113537 · Cited by 24 · see citing works

Targeting RAS in neuroblastoma: Is it possible?

Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24 · see citing works

Advances in Immunosuppressive Agents Based on Signal Pathway

Xu, Z., & Chu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.917162 · Cited by 24 · see citing works

Emerging RAS-directed therapies for cancer

Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 22 · see citing works

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

Lam, K. K., Wong, S. H., & Cheah, P. Y. (2023) · Cells · doi:10.3390/cells12040631 · Cited by 19 · see citing works

Advances in Understanding and Management of Erdheim-Chester Disease

Kulkarni, A. M., Gayam, P. K. R., & Aranjani, J. M. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122692 · Cited by 19 · see citing works

The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export

Tripathi, B. K., Hirsh, N. H., Qian, X., Durkin, M. E., Wang, D., Papageorge, A. G., Lake, R. G., Evrard, Y. A., Marcus, A. I., Ramalingam, S. S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00847-5 · Cited by 19 · see citing works

Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes

Hossain, M. T., & Hossain, M. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177432 · Cited by 20 · see citing works

Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors

Wang, Y., Liu, Y., Ge, T., Tang, J., Wang, S., Gao, Z., Chen, J., Xu, J., Gong, P., Zhao, Y., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106211 · Cited by 18 · see citing works

Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models

Tyrakis, P. A., Kampjut, D., Steele, G. F., Lindström, H. J. G., Chirnomas, D., Hopkins, B. D., Goncalves, M. D., Mukherjee, S., Cantley, L. C., & Maddocks, O. D. K. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03035-z · Cited by 17 · see citing works

Targeting Mutant KRAS for Anticancer Therapy

Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15 · see citing works

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

Nagel, A., Huegel, J., Petrilli, A. M., Rosario, R., Victoria, B., Hardin, H. M., & Fernández‐Valle, C. (2024) · Oncogene · doi:10.1038/s41388-024-02958-w · Cited by 15 · see citing works

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

Jarroudi, O. A., Chibani, H., Brahmi, S. A., & Said, A. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241284911 · Cited by 17 · see citing works

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors

Hijazi, M., Casado, P., Akhtar, N., Álvarez–Teijeiro, S., Rajeeve, V., & Cutillas, P. R. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100240 · Cited by 14 · see citing works

Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer

Jiménez, D. J., Javed, A., Rubio‐Tomás, T., Seye-Loum, N., & Barceló, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052860 · Cited by 14 · see citing works

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Ghosh, S., Fan, F., Powell, R. T., Roszik, J., Park, Y. S., STEPHAN, C. C., Sebastian, M. M., Tan, L., Sorokin, A. V., Lorenzi, P. L., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0110 · Cited by 10 · see citing works

Melanoma: Pathogenesis and Targeted Therapy

Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 10 · see citing works

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models

Ichikawa, K., Ito, S., Kato, E., Abe, N., Machida, T., Iwasaki, J., Tanaka, G., Araki, H., Wakayama, K., Jona, H., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-1037 · Cited by 9 · see citing works

Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases

Hurd, C. A., Brear, P., Revell, J. D., Ross, S. J., Mott, H. R., & Owen, D. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015735 · Cited by 9 · see citing works

A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy

Mandal, S. K., & Samanta, S. K. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673327425240815065221 · Cited by 8 · see citing works

Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review

Iovanna, J., Estarás, M., Grasso, D., Fernández-Zapico, M. E., Neira, J. L., & Santofimia‐Castaño, P. (2025) · Medicine · doi:10.1097/md.0000000000042857 · Cited by 8 · see citing works

Colon cancer cells evade drug action by enhancing drug metabolism

Cong, B., Thakur, T., Uribe, A. H., Stamou, E., Gopinath, S., Sansom, O. J., Maddocks, O. D. K., & Cagan, R. L. (2025) · Oncogene · doi:10.1038/s41388-025-03472-3 · Cited by 8 · see citing works

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Kohtamäki, L. M., Arjama, M., Mäkelä, S., Ianevski, P., Välimäki, K. E., Juteau, S., Ilmonen, S., Ungureanu, D., Kallioniemi, O., Murumägi, A., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101290 · Cited by 8 · see citing works

Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?

Vos, N. D., Hofmans, M., Lammens, T., Wilde, B. D., Roy, N. V., & Moerloose, B. D. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29930 · Cited by 8 · see citing works

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo

Fan, F., Ghosh, S., Powell, R. T., Roszik, J., Park, Y., Sobieski, M. M., Sorokin, A. V., STEPHAN, C. C., Kopetz, S., Ellis, L. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281063 · Cited by 8 · see citing works

YB-1 activating cascades as potential targets in KRAS-mutated tumors

Khozooei, S., Veerappan, S., & Toulany, M. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02092-8 · Cited by 6 · see citing works

Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer

Nakhchi, B. G., Kosuru, R., & Chrzanowska‐Wodnicka, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189853 · Cited by 6 · see citing works

Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance

Río-Vilariño, A., del Puerto‐Nevado, L., García‐Foncillas, J., & Cebrián, A. (2021) · Cancers · doi:10.3390/cancers13153757 · Cited by 6 · see citing works

Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma

Li, X., Ding, Z., & Tong, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03323-3 · Cited by 6 · see citing works

Short-Term Environmental Conditioning Enhances Tumorigenic Potential of Triple-Negative Breast Cancer Cells

Eckley, S. S., Buschhaus, J. M., Humphries, B. A., Robison, T. H., Luker, K. E., & Luker, G. D. (2019) · Tomography · doi:10.18383/j.tom.2019.00019 · Cited by 6 · see citing works

Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells

Malla, S., Nyinawabera, A., Neupane, R., Pathak, R., Lee, D., Abou-Dahech, M. S., Kumari, S., Sinha, S., Tang, Y., Ray, A., et al. (2024) · Cancers · doi:10.3390/cancers16152621 · Cited by 5 · see citing works

Targeting the KLF5/PI3K/AKT axis as a therapeutic strategy to overcome neoadjuvant chemoresistance in colorectal cancer

Gao, M., Qian, J., Xia, P., Liu, W., Jiang, Y., Xia, Y., Yao, X., Jiao, Q., & Wei, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593639 · Cited by 5 · see citing works

miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer

Pedroza, D. A., Ramirez, M., Rajamanickam, V., Subramani, R., Margolis, V., Mehmetoglu-Gurbuz, T., Estrada, A., & Lakshmanaswamy, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710337 · Cited by 6 · see citing works

A landscape of synergistic drug combinations in non-small-cell lung cancerPreprint

Nair, N. U., Greninger, P., Friedman, A. A., Amzallag, A., Cortez, E., Sahu, A. D., Lee, J. S., Dastur, A., Egan, R. K., Murchie, E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.03.447011 · Cited by 5 · see citing works

EPLIN, a prospective oncogenic molecule with contribution to growth, migration and drug resistance in pancreatic cancer

Zeng, J., Wang, C., Ruge, F., Ji, E. K., Martin, T. A., Sanders, A. J., Jia, S., Hao, C., & Jiang, W. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-81485-w · Cited by 4 · see citing works

Michael addition drugs and cancer

Tew, K. D., Townsend, D. M., Zhang, L., Zhang, X., Ye, Z., & Zhang, J. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.06.004 · Cited by 4 · see citing works

Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

Petrini, I., & Giaccone, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2599455 · Cited by 4 · see citing works

Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities

Chan, W. Y., da Silva, I. P., Long, G. V., & Rizos, H. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00199-6 · Cited by 5 · see citing works

Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer

Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 5 · see citing works

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

Peplinski, R. M., Riordan, J. D., Schillo, J. L., Hannan, E. C., Nobre, S. P., Lyons, Y. A., Ulmer, K., Goodheart, M. J., & Dupuy, A. J. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.11.016 · Cited by 3 · see citing works

Design and synthesis of multitarget triazinoindole derivatives with potent antiproliferative activity: Targeting EGFR, SIRT1, MDM2, Hsp90, PI3K, p53, and caspase-9

Badawi, W. A., Ezz-ElDien, E. S., El‐Atawy, M. A., Omar, A. Z., Hamed, E. A., Ahmed, H. A., Jaremko, M., Emwas, A.-H. M., Okda, T. M., El-Readi, M. Z., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108943 · Cited by 4 · see citing works

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer

Ghosh, S., Fan, F., Powell, R. T., Park, Y. S., STEPHAN, C. C., Kopetz, S., Ellis, L. M., & Bhattacharya, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241303302 · Cited by 3 · see citing works

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO

Labadie, B. W., Obradović, A., Raufi, A. G., Wasko, U. N., Tomassoni, L., Ge, L., May, M. S., Vij, M., Li, L., Ross, I., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00138 · Cited by 2 · see citing works

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells

Aguilar‐Valdés, A., González‐Vela, F., Sánchez‐Vidal, H., & Martínez‐Aguilar, J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300041 · Cited by 2 · see citing works

KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

Song, K. W., Ong, C. C., Lin, E., Lau, J., Sodir, N. M., Jin, D. X., Hutchinson, K. E., Xie, S., Tan, J., Liang, Y., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0995 · Cited by 2 · see citing works

CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer

Wu, R., Liu, Y., Fu, J., Zhou, T., Hu, R., Yang, B., He, Q., Yuan, T., & Zhu, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108027 · Cited by 1 · see citing works

miRNA-HK2 networks in cancer metabolism: Mechanisms and dual-targeting therapeutic opportunities

Jiang, X., Li, X., Lee, L. T. O., & Tam, K. Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189530 · Cited by 1 · see citing works

Rethinking the role of synergy calculations in the next century of drug combination discovery

Meyer, C. T., Dai, Y., Pomeroy, A. E., Twarog, N. R., Bender, A., Rosenfeld, S. S., Antonarakis, E. S., Mettetal, J. T., Huang, R. S., Quaranta, V., et al. (2026) · Med · doi:10.1016/j.medj.2026.101103 · Cited by 1 · see citing works

Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets

Buronov, A., Gaybullaev, S., Murtazaeva, Z., Ruzieva, F., Khushnazarov, Z., Turgunov, D., Nasrullaev, A., Kuryazov, R., Takhirov, Y. R., Tursunov, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167457 · Cited by 1 · see citing works

Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer

Harwansh, R. K., Hamid, J. A., Wal, P., Deshmukh, R., Patra, P. K., & Gasmi, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128334659241223113743 · Cited by 1 · see citing works

Discovery of tetracyclic 1,2,4-triazoline-fused dibenzo[b,f][1,4]oxazepine as a potent anti-colorectal cancer agent with good efficacy and low toxicity

Shi, Q., Zhou, T., Zhou, Y., Wang, Z., Xue, Y.-J., & Chen, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118203 · Cited by 1 · see citing works

PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist

Belzer, A., Bhullar, S., & Leventhal, J. S. (2022) · Current Dermatology Reports · doi:10.1007/s13671-022-00365-6

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapyPreprint

Seghers, S., Compte, M. L., Fortes, F. R., Roeyen, G., Hartman, V., Hendriks, J. M., Schil, P. E. V., Komen, N., Vercammen, H., Peeters, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7614104/v1

Additional file 1 of Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma

Li, X., Ding, Z., & Tong, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25706142

Additional file 2 of Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma

Li, X., Ding, Z., & Tong, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26713370

Emerging therapeutic strategies for mitochondrial DNA-related diseases

Shi, R., Falabella, M., Aref, J., Hanna, M. G., Minczuk, M. A., Viscomi, C. F., & Pitceathly, R. D. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102841

Screening of shared molecular markers between cervical cancer and major depressive disorder and the mechanism of CRAT/CLIC4 regulating EMT in cervical cancer cells

Zhang, H.-H., Liu, M., Chen, Y.-N., Ming-ru, Z., Zhang, J., & He, J. (2026) · BMC Cancer · doi:10.1186/s12885-026-16571-5

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Shapiro, G. I., LoRusso, P. M., Cho, D. C., Musib, L. C., Yan, Y., Wongchenko, M. J., Chang, I., Patel, P. H., Chan, I. T., Bohorquez, S. M. S., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00975-6 · Cited by 31 · see citing works

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Weekes, C. D., Lockhart, A. C., LoRusso, P. M., Murray, E. R., Park, E., Tagen, M., Singh, J., Sarkar, I., Müeller, L., Dokainish, H., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0292 · Cited by 58 · see citing works

Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors

Bendell, J. C., LoRusso, P. M., Cho, D. C., Musib, L. C., Yan, Y., Chang, I., Patel, P. H., Chang, I. T., Meng, R. D., & Shapiro, G. I. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct328 · Cited by 6 · see citing works

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Rosen, L. S., LoRusso, P. M., Ma, W. W., Goldman, J. W., Weise, A. M., Colevas, A. D., Adjei, A. A., Yazji, S., Shen, A., Johnston, S. H., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0374-3 · Cited by 88 · see citing works

Abstract CT107: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

Weekes, C. D., Lockhard, A., LoRusso, P. M., Murray, E. R., Park, E., Tagen, M., Müeller, L., Dokainish, H., Shapiro, G. I., & Burris, H. A. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct107 · Cited by 11 · see citing works